Status:
COMPLETED
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
Lead Sponsor:
Helsinn Therapeutics (U.S.), Inc
Conditions:
Cancer Cachexia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to...
Eligibility Criteria
Inclusion
- Community-dwelling patients ≥ 18 years of age with incurable,histologically diagnosed cancer.
- Involuntary loss of body weight of ≥ 5 % within the past 6 months
Exclusion
- Presently hospitalized or in a nursing care facility.
- Inability to increase food intake from secondary causes.
- Liver disease
- If female-pregnant, breast-feeding or of childbearing potential.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00267358
Start Date
November 1 2005
End Date
October 1 2006
Last Update
September 2 2013
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Palo Verde Hematology Oncology Ltd.
Glendale, Arizona, United States, 85304
2
Comprehensive Blood & Cancer Center
Bakersfield, California, United States, 93309
3
Pacific Oncology & Hematology Associates
Encinitas, California, United States, 92024
4
Pacific Oncology and Hematology Associates
Encinitas, California, United States, 92024